Common Antihypertensive Medications in CKD and Hypertension
For patients with CKD and hypertension, start with a renin-angiotensin system inhibitor (ACE inhibitor or ARB) as first-line therapy, particularly if albuminuria is present, then add a calcium channel blocker or diuretic as second-line agents to achieve blood pressure targets. 1
First-Line Therapy: RAS Inhibitors
The KDIGO 2021 guidelines provide clear, evidence-based recommendations for initial antihypertensive selection:
- ACE inhibitors or ARBs are strongly recommended for patients with CKD stages G1-G4 and severely increased albuminuria (A3), regardless of diabetes status 1
- ACE inhibitors or ARBs are also recommended for patients with diabetes and moderately-to-severely increased albuminuria (A2-A3) 1
- Even for patients with moderately increased albuminuria (A2) without diabetes, RAS inhibitors are suggested 1
The rationale is compelling: RAS inhibitors demonstrate superior efficacy in reducing proteinuria and slowing CKD progression 2, and recent data shows they are associated with lower odds of sustained hypertension (OR 0.60) and nocturnal hypertension (OR 0.71) 3.
Critical implementation point: Use the highest approved tolerated dose of ACE inhibitor or ARB, as trial benefits were achieved at these doses 1. Monitor serum creatinine and potassium within 2-4 weeks of initiation or dose increases 1.
Second-Line Agents
When RAS inhibition alone is insufficient (which is common), add:
Calcium Channel Blockers
- Long-acting dihydropyridine CCBs are effective second-line agents 4
- Particularly useful for blood pressure control and cardiovascular parameters 2
- Important caveat: CCBs may be associated with nocturnal hypertension (OR 1.36) 3, though they remain guideline-recommended
Diuretics
- Thiazide or thiazide-like diuretics for earlier CKD stages 5
- Loop diuretics become necessary as GFR declines 1
- Chlorthalidone specifically shows efficacy even in stage 4 CKD and can mitigate hyperkalemia risk when combined with other agents 4
Additional Therapeutic Considerations
For Resistant Hypertension
Mineralocorticoid receptor antagonists (spironolactone) are recommended for refractory hypertension 1, though hyperkalemia risk requires careful monitoring, particularly with eGFR <45 mL/min/1.73m² 1.
Emerging Agents
Recent evidence supports considering:
- SGLT-2 inhibitors for cardiovascular and kidney protection, though BP-lowering effects are modest 5
- Non-steroidal MRAs as alternatives to spironolactone with lower hyperkalemia risk 6, 5
Critical Management Pitfalls
Avoid combining ACE inhibitors, ARBs, and direct renin inhibitors - this triple combination is contraindicated due to increased adverse events without additional benefit 1.
Do not discontinue RAS inhibitors prematurely: Continue therapy unless creatinine rises >30% within 4 weeks of initiation, or in cases of symptomatic hypotension or uncontrolled hyperkalemia despite medical management 1. Hyperkalemia can often be managed with dietary modification and potassium binders rather than stopping beneficial medications 1, 6.
Beta-blockers are notably absent from first-line recommendations and may actually increase masked uncontrolled hypertension (OR 1.48) and nocturnal hypertension (OR 1.33) in CKD patients 3.
Blood Pressure Targets
Target systolic BP <120 mmHg when tolerated using standardized office measurement 1, though <130/80 mmHg is acceptable for those at higher cardiovascular risk 6. This intensive target requires standardized measurement technique - applying the <120 mmHg target to non-standardized measurements is potentially hazardous 1.